1. Gordon, D. J. et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation
79, 8–15. https://doi.org/10.1161/01.cir.79.1.8 (1989).
2. Sharrett, A. R. et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 104,
1108–1113. https://doi.org/10.1161/hc3501.095214 (2001).
3. Moore, R. E. et al. Apolipoprotein A-I deficiency results in markedly increased atherosclerosis in mice lacking the LDL receptor.
Arterioscler. Thromb. Vasc. Biol. 23, 1914–1920. https://doi.org/10.1161/01.ATV.0000092328.66882.F5 (2003).
4. Zabalawi, M. et al. Induction of fatal inflammation in LDL receptor and ApoA-I double-knockout mice fed dietary fat and cholesterol. Am. J. Pathol. 163, 1201–1213. https://doi.org/10.1016/S0002-9440(10)63480-3 (2003).
5. Badimon, J. J., Badimon, L. & Fuster, V. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the
cholesterol-fed rabbit. J. Clin. Investig. 85, 1234–1241. https://doi.org/10.1172/JCI114558 (1990).
6. Schwartz, G. G. et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N. Engl. J. Med. 367, 2089–2099.
https://doi.org/10.1056/NEJMoa1206797 (2012).
7. Barter, P. J. et al. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357, 2109–2122. https://doi.org/
10.1056/NEJMoa0706628 (2007).
8. Kathiresan, S. Will cholesteryl ester transfer protein inhibition succeed primarily by lowering low-density lipoprotein cholesterol?
Insights from human genetics and clinical trials. J. Am. Coll. Cardiol. 60, 2049–2052. https://doi.org/10.1016/j.jacc.2012.08.967
(2012).
9. Rothblat, G. H. et al. Cell cholesterol efflux: Integration of old and new observations provides new insights. J. Lipid Res. 40, 781–796.
https://doi.org/10.1016/S0022-2275(20)32113-1 (1999).
10. Khera, A. V. et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N. Engl. J. Med. 364, 127–135.
https://doi.org/10.1056/NEJMoa1001689 (2011).
11. Rohatgi, A. et al. HDL cholesterol efflux capacity and incident cardiovascular events. N. Engl. J. Med. 371, 2383–2393. https://doi.
org/10.1056/NEJMoa1409065 (2014).
12. Saleheen, D. et al. Association of HDL cholesterol efflux capacity with incident coronary heart disease events: A prospective casecontrol study. Lancet Diabetes Endocrinol. 3, 507–513. https://doi.org/10.1016/S2213-8587(15)00126-6 (2015).
13. Rohatgi, A. High-density lipoprotein function measurement in human studies: Focus on cholesterol efflux capacity. Prog. Cardiovasc. Dis. 58, 32–40. https://doi.org/10.1016/j.pcad.2015.05.004 (2015).
Scientific Reports |
(2023) 13:1899 |
https://doi.org/10.1038/s41598-023-28953-x
Vol.:(0123456789)
www.nature.com/scientificreports/
14. Harada, A. et al. Cholesterol uptake capacity: A new measure of HDL functionality for coronary risk assessment. J. Appl. Lab. Med.
2, 186–200. https://doi.org/10.1373/jalm.2016.022913 (2017).
15. Toh, R. Assessment of HDL cholesterol removal capacity: Toward clinical application. J. Atheroscler. Thromb. 26, 111–120. https://
doi.org/10.5551/jat.RV17028 (2019).
16. Nagano, Y. et al. Impaired cholesterol-uptake capacity of HDL might promote target-lesion revascularization by inducing neoatherosclerosis after stent implantation. J. Am. Heart Assoc. 8, e011975. https://doi.org/10.1161/JAHA.119.011975 (2019).
17. Oshita, T. et al. Association of cholesterol uptake capacity, a novel indicator for HDL functionality, and coronary plaque properties:
An optical coherence tomography-based observational study. Clin. Chim. Acta 503, 136–144. https://doi.org/10.1016/j.cca.2020.
01.001 (2020).
18. Watanabe, T. et al. Development of fully automated and ultrasensitive assays for urinary adiponectin and their application as novel
biomarkers for diabetic kidney disease. Sci. Rep. 10, 15869. https://doi.org/10.1038/s41598-020-72494-6 (2020).
19. Shao, B., Pennathur, S. & Heinecke, J. W. Myeloperoxidase targets apolipoprotein A-I, the major high density lipoprotein protein,
for site-specific oxidation in human atherosclerotic lesions. J. Biol. Chem. 287, 6375–6386. https://doi.org/10.1074/jbc.M111.
337345 (2012).
20. Huang, Y. et al. An abundant dysfunctional apolipoprotein A1 in human atheroma. Nat. Med. 20, 193–203. https://doi.org/10.
1038/nm.3459 (2014).
21. Saeedi, R., Li, M. & Frohlich, J. A review on lecithin:cholesterol acyltransferase deficiency. Clin. Biochem. 48, 472–475. https://doi.
org/10.1016/j.clinbiochem.2014.08.014 (2015).
22. DiDonato, J. A. et al. Function and distribution of apolipoprotein A1 in the artery wall are markedly distinct from those in plasma.
Circulation 28, 1644–1655. https://doi.org/10.1161/CIRCULATIONAHA.113.002624 (2013).
23. Kuno, A. et al. LecT-Hepa: A triplex lectin-antibody sandwich immunoassay for estimating the progression dynamics of liver
fibrosis assisted by a bedside clinical chemistry analyzer and an automated pretreatment machine. Clin. Chim. Acta 412, 1767–1772.
https://doi.org/10.1016/j.cca.2011.05.028 (2011).
24. An, J. et al. Evaluation of the HISCL anti-Treponema pallidum assay as a screening test for syphilis. Clin. Vaccine Immunol. 22,
817–822. https://doi.org/10.1128/CVI.00116-15 (2015).
25. De Grande, L. A. C. et al. Standardization of free thyroxine measurements allows the adoption of a more uniform reference interval.
Clin. Chem. 63, 1642–1652. https://doi.org/10.1373/clinchem.2017.274407 (2017).
26. Mei, H. et al. Evaluation the combined diagnostic value of TAT, PIC, tPAIC, and sTM in disseminated intravascular coagulation:
A multi-center prospective observational study. Thromb. Res. 173, 20–26. https://doi.org/10.1016/j.thromres.2018.11.010 (2019).
27. Komatsu-Fujii, T. et al. Serum TARC levels are strongly correlated with blood eosinophil count in patients with drug eruptions.
Allergol. Int. 66, 116–122. https://doi.org/10.1016/j.alit.2016.06.003 (2017).
28. Goto, M. et al. Analytical performance of a new automated chemiluminescent magnetic immunoassays for soluble PD-1, PD-L1,
and CTLA-4 in human plasma. Sci. Rep. 9, 10144. https://doi.org/10.1038/s41598-019-46548-3 (2019).
29. Phillips, M. C. Molecular mechanisms of cellular cholesterol efflux. J. Biol. Chem. 289, 24020–24029. https://doi.org/10.1074/jbc.
R114.583658 (2014).
30. Jin, Z. et al. Development and validation of apolipoprotein AI-associated lipoprotein proteome panel for the prediction of cholesterol efflux capacity and coronary artery disease. Clin. Chem. 65, 282–290. https://doi.org/10.1373/clinchem.2018.291922 (2019).
31. Horiuchi, Y. et al. Validation and application of a novel cholesterol efflux assay using immobilized liposomes as a substitute for
cultured cells. Biosci. Rep. 38, BSR20180144. https://doi.org/10.1042/BSR20180144 (2018).
32. Neufeld, E. B. et al. ApoA-I-mediated lipoprotein remodeling monitored with a fluorescent phospholipid. Biology (Basel) 8, 53.
https://doi.org/10.3390/biology8030053 (2019).
33. Brahimaj, A. et al. Serum levels of apolipoproteins and incident type 2 diabetes: A prospective cohort study. Diabetes Care 40,
346–351. https://doi.org/10.2337/dc16-1295 (2017).
34. Hottman, D. A., Chernick, D., Cheng, S., Wang, Z. & Li, L. HDL and cognition in neurodegenerative disorders. Neurobiol. Dis. 2,
22–36. https://doi.org/10.1016/j.nbd.2014.07.015 (2014).
35. Ren, L. et al. Apolipoproteins and cancer. Cancer Med. 8, 7032–7043. https://doi.org/10.1002/cam4.2587 (2019).
36. Brites, F., Martin, M., Guillas, I. & Kontush, A. Antioxidative activity of high-density lipoprotein (HDL): Mechanistic insights into
potential clinical benefit. BBA Clin. 8, 66–77. https://doi.org/10.1016/j.bbacli.2017.07.002 (2017).
37. Button, E. B. et al. HDL from an Alzheimer’s disease perspective. Curr. Opin. Lipidol. 30, 224–234. https://doi.org/10.1097/MOL.
0000000000000604 (2019).
38. Sankaranarayanan, S. et al. A sensitive assay for ABCA1-mediated cholesterol efflux using BODIPY-cholesterol. J. Lipid Res. 52,
2332–2340. https://doi.org/10.1194/jlr.D018051 (2011).
Author contributions
A.H., R.T., and K.H. conceived the project. Ka.M., A.H., and R.T. designed the study concept and wrote the
manuscript. T.K., S.U., and Y.N. designed and synthesized Bio-PEG3-cholesterol. Ka.M., Ke.M., J.K., M.K., T.I.,
and K.A. established assays for CUC. R.T., M.N., and T.I. collected samples and interpreted the clinical data. All
authors read and approved the final version of the manuscript.
Competing interests The authors declare no competing interests.
Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/
10.1038/s41598-023-28953-x.
Correspondence and requests for materials should be addressed to A.H. or R.T.
Reprints and permissions information is available at www.nature.com/reprints.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and
institutional affiliations.
Scientific Reports |
Vol:.(1234567890)
(2023) 13:1899 |
https://doi.org/10.1038/s41598-023-28953-x
10
www.nature.com/scientificreports/
Open Access This article is licensed under a Creative Commons Attribution 4.0 International
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the
Creative Commons licence, and indicate if changes were made. The images or other third party material in this
article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the
material. If material is not included in the article’s Creative Commons licence and your intended use is not
permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
© The Author(s) 2023
Scientific Reports |
(2023) 13:1899 |
https://doi.org/10.1038/s41598-023-28953-x
11
Vol.:(0123456789)
...
論文の公開元へ
